An interview featuring Dr. Rosmarin regarding the recent phase 3 TRuE-V trials on ruxolitinib and nonsegmental vitiligo treatment.
Tim Smith
Advertisement
Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at [email protected].
Articles by Tim Smith
A discussion regarding the main data points from the Phase 3 TRuE-V clinical trial program assessing the use of ruxolitinib cream for nonsegmental vitiligo.
New research demonstrated a correlation between specific VDR polymorphisms and patients’ liability of having vitiligo.
A discussion with the moderator of the Global Parents for Eczema Research symposium regarding climate change and the effects of fire, drought, airborne pollution on atopic dermatitis.
A discussion with Dr. Boos on the topic of climate change and airborne pollution exposure leading to or exacerbating atopic dermatitis.
A discussion with Dr. Lal on the topics of benefits of ruxolitinib treatment for nonsegmental vitiligo, as well as on the recent recall of hair products due to benzene risk.
A recent research letter highlighted a case observed in Japan in which a patient with alopecia totalis, and an associated case of atopic dermatitis, was treated effectively with baricitinib, a JAK inhibitor.
Recent phase 3 trial data suggests the efficacy across multiple endpoints of roflumilast foam as a treatment for seborrheic dermatitis.
New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.
Recent clinical trial data from UNCOVER-1 and UNCOVER-2 demonstrated the positive effects of ixekizumab use in adult plaque psoriasis patients.
During a recent interview regarding ReOpen1 and ReOpen2 trials, Dr. Mahmoud described a new treatment device for chronic rhinosinusitis patients.
The recent GUIDE study examined the efficacy of guselkumab for moderate-to-severe plaque psoriasis, finding it consistent with previous trials.
Recent phase 3 trial results suggest positive effects and faster onset using CAL/BDP cream for adult plaque psoriasis.
A discussion regarding the use of plaque psoriasis treatments such as apremilast, ixekizumab, and methotrexate.
When compared to an intervention system guided by a therapist, a newly-designed self care system for atopic dermatitis patients may be as helpful.
Dr. Chopra elaborated on his Pri-Med Midwest 2022 presentation regarding the future of advances in medicine, specifically highlighting artificial intelligence, gut microbiome research, and gene editing.
Dr. Chopra described several key points of his Pri-Med Midwest presentation regarding the future of advances in medicine, including artificial intelligence, gut bacteria, and CRISPR technology.
A highlighted description of some key takeaways from presentations at Pri-Med Midwest 2022, including such topics as infectious disease, monkeypox, colorectal cancer, psoriasis, and COVID-19.
An interview with Dr. Anwuri regarding her Pri-Med Midwest presentation on treating adult plaque psoriasis.
In an interview during Pri-Med Midwest, Dr. Kushner spoke about the benefits of treating obesity and diabetes synchronously.
A discussion with Dr. Vega regarding colorectal cancer screenings, aspirin use recommendations, and the current state of healthcare.
Charles Vega, MD: Atrial Fibrillation, Risk Factors for Autosomal Dominant Polycystic Kidney Disease
An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.
A discussion with Dr. Angarone regarding his presentation at Pri-Med Midwest, exploring the topic of treating infectious disease in developing countries.
A discussion regarding highlights from Dr. Charles Vega’s presentation on common urgent care presentations and concerns regarding acute pain.
Dr. Angarone highlighted several key takeaways from his presentation at Pri-Med Midwest.
A discussion regarding highlights from Dr. Michael Angarone’s presentation on emerging infectious diseases.
Research suggests disparities between racial and ethnic groups exist among patients with Alzheimer’s disease and related dementias.
A recent study confirmed the safety of tralokinumab with regard to COVID-19 and related vaccinations.
Researchers evaluated the use of IVIG for patients with the rare autoimmune disorder dermatomyositis.
A recent cohort study of 20 emergency departments assessed allergic contact dermatitis cases.
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
Omalizumab-Facilitated OIT Enables Maintenance Dosing in Food Allergy
2
After Sickle Cell Gene Therapy, What Comes Next?
3
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
4
Namilumab Fails to Meet Primary End Point in Pulmonary Sarcoidosis
5